Chemical Nameevinacumab-dgnb
Dosage FormInjection (intravenous; 345 mg/2.3 mL (150 mg/mL), 1,200 mg/8 mL (150 mg/mL))
Drug ClassMonoclonal antibodies
CompanyRegeneron Pharmaceuticals
Approval Year2021


  • Indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia
Last updated on 3/14/2022

More on this drug: Clinical Trials

Document TitleYearSource
Evkeeza (evinacumab-dgnb) Prescribing Information.2021Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Document TitleYearSource
Assessment report: evkeeza. 2021EMA
Document TitleYearSource
Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis. 2021Journal of Cardiovascular Pharmacology

Have we missed a study, or would you like to comment on a study?